Opinion

Video

Adjuvant CDK 4/6 Inhibitors for High-Risk HR+/HER2– Early Breast Cancer: Toxicity Management and Real-World Data

Panelists discuss the factors influencing the choice between abemaciclib and ribociclib for adjuvant CDK4/6 inhibitor therapy, including patient characteristics and safety profiles, and explore strategies for toxicity management, maintaining dose intensity, and addressing adherence or toxicity challenges in real-world clinical practice.

Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected

    Video content above is prompted by the following:

    • What specific patient characteristics influence your choice between abemaciclib and ribociclib?
    • In which scenarios would you preferentially choose abemaciclib over ribociclib? Ribociclib over abemaciclib?
    • Could you discuss your approach to toxicity management with adjuvant CDK4/6 inhibitors?
    • How do the different safety profiles of abemaciclib and ribociclib impact your patient selection? How do you weigh clinical considerations and comorbidities in your selection considerations?
    • What strategies have you found most effective for maintaining dose intensity while managing adverse effects?
    • How has real-world experience with adjuvant CDK4/6 inhibitors matched up with clinical trial data?
    • What have been your key learnings about patient selection and management?
    • How do you handle patients who struggle with adherence or toxicity in the first few months?
    Related Content